380 results on '"Lüftner, Diana"'
Search Results
2. Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
3. How detection of immune-related adverse events fails during transfer of patients between medical sectors
4. What do hematologists and oncologists consider necessary for their career? Results of an online survey in Germany, Austria and Switzerland
5. PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant
6. Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer
7. CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs
8. Discussion of ABC7 Consensus and German Recommendations
9. Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry
10. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024
11. Systemic therapy of metastatic breast cancer: a plea for confirmation of subtypes by genomic assays
12. Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies
13. Treatment of Early Breast Cancer
14. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
15. ABC7 Consensus: Assessment by a German Group of Experts.
16. Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer
17. Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer
18. Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer
19. Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer
20. Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer
21. Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer
22. Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer
23. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023
24. Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer
25. Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies
26. Abstract P4-01-01: RIBANNA 5th interim analysis: Matched-pair analysis of progression-free survival (PFS) across treatment cohorts and comparison of frontline ribociclib + endocrine therapy PFS data from RIBANNA vs MONALEESA trials, in HR+, HER2– ABC
27. Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer
28. Abstract P2-01-01: Interim analysis (n=200) from ELEANOR: a multi-national, prospective, non-interventional study among patients with HER2+ and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routine
29. Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer
30. Abstract P4-01-03: Progression-free survival and patient-reported outcomes in HR+, HER2– ABC patients treated with first-line ribociclib + endocrine therapy (ET) or ET monotherapy or chemotherapy in real world setting: 5th interim analysis of RIBANNA
31. Abstract P4-01-05: Machine learning to predict treatment response and tolerability in HR+, HER2– advanced breast cancer: German study AI4ANNA
32. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023
33. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023
34. Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer : Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel
35. Update Mammakarzinom 2022 Teil 6 : Brustkrebs in fortgeschrittenen Krankheitsstadien
36. Update Mammakarzinom 2022 Teil 5 : Brustkrebs in frühen Krankheitsstadien
37. Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network
38. What do hematologists and oncologists consider necessary for their career? Results of an online survey in Germany, Austria and Switzerland
39. Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus
40. AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022
41. Advanced Breast Cancer
42. Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer
43. Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer
44. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT
45. Update Breast Cancer 2022 Part 1 – Early Stage Breast Cancer
46. Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer
47. The Managing Advanced Cancer Pain Together (MACPT) conversation tool: an evaluation of use in clinical practice
48. Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference
49. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
50. Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.